Sarepta Therapeutics Crisis - Search News

Order byBest matchMost fresh

News

Sarepta may not survive its current gene therapy crisis

Why Sarepta may not survive its current gene therapy crisis

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein writes. But it's an accurate reflection of the situation.

Continue reading

BioPharma Dive · 4d

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

· 3d · on MSN

Sarepta’s Duchenne Therapy Sparked Fears Even Before FDA’s Order

7d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

4don MSN

Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse.

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Fierce Biotech7d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

4d

Sarepta stops Elevidys shipments after standoff with FDA

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" with the regulator.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results